PriceTargets.com logo

AEON Biopharma - AEON Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.00
  • Forecasted Upside: 241.30%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$0.29 As of 07/31/2026 05:00 PM ET
▲ +0.0378 (14.81%)

This chart shows the closing price for AEON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AEON Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AEON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AEON

Analyst Price Target is $1.00
▲ +241.30% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for AEON Biopharma in the last 3 months. The average price target is $1.00, with a high forecast of $1.00 and a low forecast of $1.00. The average price target represents a 241.30% upside from the last price of $0.29.

This chart shows the closing price for AEON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in AEON Biopharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2026
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2026
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/1/2026
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2026

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/30/2026Lake Street CapitalInitiated CoverageBuy$1.00
5/27/2026Zacks ResearchUpgradeHold
11/18/2025Zacks ResearchUpgradeHold
11/14/2025HC WainwrightUpgradeStrong-Buy
10/8/2025AegisReiterated RatingBuy ➝ Buy
10/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$360.00 ➝ $360.00
8/14/2024HC WainwrightLower TargetBuy ➝ Buy$432.00 ➝ $360.00
7/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$432.00 ➝ $432.00
5/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$432.00 ➝ $432.00
5/15/2024HC WainwrightLower TargetBuy ➝ Buy$1,296.00 ➝ $432.00
5/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$1,296.00
4/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$1,296.00
8/18/2023HC WainwrightInitiated CoverageBuy$1,296.00
(Data available from 8/1/2021 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2026
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2026

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
AEON Biopharma logo
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
Read More

Today's Range

Now: $0.29
Low: $0.25
High: $0.34

50 Day Range

MA: $0.58
Low: $0.24
High: $0.78

52 Week Range

Now: $0.29
Low: $0.22
High: $1.45

Volume

7,047,681 shs

Average Volume

630,243 shs

Market Capitalization

$7.41 million

P/E Ratio

1.63

Dividend Yield

N/A

Beta

0.61

Frequently Asked Questions

What sell-side analysts currently cover shares of AEON Biopharma?

The following equities research analysts have issued reports on AEON Biopharma in the last twelve months: Aegis, HC Wainwright, Lake Street Capital, and Zacks Research.
View the latest analyst ratings for AEON.

What is the current price target for AEON Biopharma?

0 Wall Street analysts have set twelve-month price targets for AEON Biopharma in the last year. Their average twelve-month price target is $1.00, suggesting a possible upside of 241.3%. Lake Street Capital has the highest price target set, predicting AEON will reach $1.00 in the next twelve months. Lake Street Capital has the lowest price target set, forecasting a price of $1.00 for AEON Biopharma in the next year.
View the latest price targets for AEON.

What is the current consensus analyst rating for AEON Biopharma?

AEON Biopharma currently has 1 hold rating, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AEON will outperform the market and that investors should add to their positions of AEON Biopharma.
View the latest ratings for AEON.

What other companies compete with AEON Biopharma?

Other companies that are similar to AEON Biopharma include Actuate Therapeutics, Synaptogenix, Barinthus Biotherapeutics, TherapeuticsMD and Polyrizon. Learn More about companies similar to AEON Biopharma.

How do I contact AEON Biopharma's investor relations team?

AEON Biopharma's physical mailing address is 300 SE 2nd Street, Suite 600, Fort Lauderdale, FL 33301, United States. The company's listed phone number is 754-220-9229. The official website for AEON Biopharma is www.aeonbiopharma.com. Learn More about contacing AEON Biopharma investor relations.